The U.S. Food and Drug Administration has issued an untitled letter to Alar Pharmaceuticals over misleading promotional claims about an investigational ketamine treatment.
The FDA’s Office of Prescription Drug Promotion issued the letter on August 21, targeting claims made about ALA-3000, a ketamine pamoate drug candidate for treatment-resistant depression.
OPDP representatives observed the misleading materials at Alar’s exhibit booth and in a brochure distributed at the American Psychiatric Association’s annual meeting in May 2026.
The FDA took particular exception to several specific claims made in the exhibit materials and the distributed brochure promoting ALA-3000 to psychiatric professionals.
Among the flagged statements was the claim that ALA-3000 offers a “sustained-release profile for weeks without pronounced initial burst or dose dumping effect.”
The agency also objected to assertions that the drug produces “no overall sedative, dissociative, psychosis-like side effects” and carries “no abuse signals.”
Another claim that drew scrutiny was the suggestion that ALA-3000 “potentially eliminates the mandatory 2-hour post-dose on-site monitoring required with ketamine therapies.”
The FDA said these claims “are extremely concerning given the lack of adequate safety and efficacy data for ALA-3000,” underlining the seriousness of the enforcement action.
Alar Pharmaceuticals has been given 15 working days from receipt of the letter to identify any other promotional materials containing similar representations and explain how it intends to discontinue their use.
Alternatively, the company may provide its own reasoning and supporting evidence if it chooses to dispute the FDA’s findings within that same timeframe.
The letter marks the 21st untitled letter issued in 2026 by OPDP as part of the agency’s broader push to crack down on illegal prescription drug advertising.
This action against Alar follows similar enforcement letters sent to major pharmaceutical companies this year, including Sanofi, Viatris, Lundbeck, Bayer, Pfizer, and Novo Nordisk.
The FDA also notably issued an untitled letter in November targeting PharmaTher over a generic ketamine product, citing misrepresentation of the drug’s approved uses on a company webpage.
The Alar letter is the first of its kind issued by OPDP in over a month, and its recipient’s name was redacted, a departure from the agency’s recent practice of publicly identifying letter recipients.